Pfizer Inc. $PFE Stock Holdings Lifted by Trexquant Investment LP

Key Points

• Trexquant Investment LP increased its stake in Pfizer Inc. by 137.3% in the first quarter, now holding approximately 1.8 million shares valued at $46 million.
• Several institutional investors have also boosted their positions in Pfizer, with a total of 68.36% of the stock owned by hedge funds and other institutional investors.
• Pfizer recently reported earnings of $0.78 EPS for the quarter, surpassing estimates and showing a 10.3% year-over-year revenue increase, with a new dividend of $0.43 set for September.

Trexquant Investment LP lifted its position in Pfizer Inc. (NYSE:PFE - Free Report) by 137.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,817,207 shares of the biopharmaceutical company's stock after acquiring an additional 1,051,471 shares during the period. Pfizer comprises approximately 0.5% of Trexquant Investment LP's holdings, making the stock its 13th largest position. Trexquant Investment LP's holdings in Pfizer were worth $46,048,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in PFE. Gerber Kawasaki Wealth & Investment Management boosted its holdings in shares of Pfizer by 4.8% during the first quarter. Gerber Kawasaki Wealth & Investment Management now owns 21,623 shares of the biopharmaceutical company's stock worth $548,000 after purchasing an additional 987 shares during the period. Huber Capital Management LLC lifted its stake in Pfizer by 17.4% in the first quarter. Huber Capital Management LLC now owns 573,288 shares of the biopharmaceutical company's stock valued at $14,527,000 after acquiring an additional 85,000 shares during the last quarter. Landscape Capital Management L.L.C. lifted its stake in Pfizer by 38.7% in the first quarter. Landscape Capital Management L.L.C. now owns 41,077 shares of the biopharmaceutical company's stock valued at $1,041,000 after acquiring an additional 11,469 shares during the last quarter. Oak Associates Ltd. OH lifted its stake in Pfizer by 1.7% in the first quarter. Oak Associates Ltd. OH now owns 407,682 shares of the biopharmaceutical company's stock valued at $10,331,000 after acquiring an additional 6,982 shares during the last quarter. Finally, Oarsman Capital Inc. lifted its stake in Pfizer by 3.1% in the first quarter. Oarsman Capital Inc. now owns 34,604 shares of the biopharmaceutical company's stock valued at $877,000 after acquiring an additional 1,035 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of a number of analyst reports. The Goldman Sachs Group lifted their target price on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Jefferies Financial Group lifted their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a research note on Wednesday, May 21st. Redburn Atlantic reduced their target price on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Bank of America boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Wolfe Research boosted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Pfizer has an average rating of "Hold" and an average price target of $28.12.

Pfizer Trading Up 0.6%

Shares of PFE stock opened at $25.08 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm's fifty day simple moving average is $24.76 and its 200 day simple moving average is $24.40. The firm has a market capitalization of $142.57 billion, a P/E ratio of 13.34, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.